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A B S T R A C T
Microﬂuidics has recently emerged as a new method of manufacturing liposomes, which allows for
reproducible mixing in miliseconds on the nanoliter scale. Here we investigate microﬂuidics-based
manufacturing of liposomes. The aim of these studies was to assess the parameters in a microﬂuidic
process by varying the total ﬂow rate (TFR) and the ﬂow rate ratio (FRR) of the solvent and aqueous
phases. Design of experiment and multivariate data analysis were used for increased process
understanding and development of predictive and correlative models. High FRR lead to the bottom-
up synthesis of liposomes, with a strong correlation with vesicle size, demonstrating the ability to in-
process control liposomes size; the resulting liposome size correlated with the FRR in the microﬂuidics
process, with liposomes of 50 nm being reproducibly manufactured. Furthermore, we demonstrate the
potential of a high throughput manufacturing of liposomes using microﬂuidics with a four-fold increase
in the volumetric ﬂow rate, maintaining liposome characteristics. The efﬁcacy of these liposomes was
demonstrated in transfection studies and was modelled using predictive modeling. Mathematical
modelling identiﬁed FRR as the key variable in the microﬂuidic process, with the highest impact on
liposome size, polydispersity and transfection efﬁciency. This study demonstrates microﬂuidics as a
robust and high-throughput method for the scalable and highly reproducible manufacture of size-
controlled liposomes. Furthermore, the application of statistically based process control increases
understanding and allows for the generation of a design-space for controlled particle characteristics.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Liposomes are well established as delivery systems and
immunological adjuvants and there are a wide range of methods
employed in their production. For example, multilamellar vesicles
(MLV) can be formed by the dispersion of a dried lipid ﬁlm and
small unilamellar vesicles (SUV) can then be produced by
sonication (Lapinski et al., 2007; Maulucci et al., 2005), extrusion
(de Paula Rigoletto et al., 2012; Olson et al., 1979), or high-pressure
homogenization (Barnadas-Rodriguez and Sabes, 2001; Pupo et al.,
2005). However, sonication may lead to sample contamination by
metallic residues from the probe tip, lipid degradation and lack of
scalability (Wagner and Vorauer-Uhl, 2011). Homogenization* Corresponding author. Tel.: +44 0 121 204 3991; fax: +44 0 121 359 0733.
E-mail address: y.perrie@aston.ac.uk (Y. Perrie).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijpharm.2014.10.030
0378-5173/ã 2014 The Authors. Published by Elsevier B.V. This is an open access article untechniques, shear or pressure induced size reduction, circumvent
protein or lipid degradation and are frequently used to reduce the
size and lamellarity of MLV (Wagner and Vorauer-Uhl, 2011).
Maintenance of constant temperatures throughout these process-
es can be difﬁcult, with restrictions to relatively small working
volumes and quantities; however, continuous and heat controlled
homogenization techniques have been developed to help over-
come some of these problems (Riaz, 1996; Wagner and Vorauer-
Uhl, 2011).
As an alternative to these methods, microﬂuidics is a relatively
new area of liposome synthesis, where the small dimensions in a
micromixer allow for fast mixing, dominated by diffusion or
convection (Whitesides, 2006). Microﬂuidics refers to ﬂuid
handling methods in a controlled volume, typically below
millimeter scales, which allows for implementation of the mixing
process into planar chips (Squires and Quake, 2005). The
application of microﬂuidics for liposome synthesis in novel
lab-on-a-chip based devices dramatically reduces time for sampleder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and may additionally be fully software controlled to aid process
robustness and reproducibility (van Swaay, 2013). Various micro-
mixers have been designed and applied for the manufacturing of
liposomes based on different channel layouts (Pradhan et al., 2008)
including ﬂow focusing (Davies et al., 2012; Jahn et al., 2004),
droplet based (Teh et al., 2008), and T- or Y- shaped mixers
(Kurakazu and Takeuchi, 2010). In this study, a staggered
herringbone micromixer (SHM) (Stroock et al., 2002) which
induces chaotic advection, is used. The chaotic advection mixing
proﬁle allows for stretching and folding of ﬂuid streams over the
channels cross-sectional area, increasing mass transfer together
with the herringbone type structures on the channel ﬂoor (Stroock
et al., 2002). Here, a SHM was used together with the automated
mixing platform NanoAssemblrTM (Precision NanoSystems, Inc.).
This system enables rapid, reproducible and scalable manufacture
of homogeneous next-generation nanoparticles and liposomes
(Belliveau et al., 2012; Zhigaltsev et al., 2012). Lipid dissolved in
solvent is pumped into one inlet and aqueous buffer into the other
inlet of the microﬂuidic mixing cartridge (Fig. 1). It has been
suggested that a nanoprecipitation reaction results in the
formation of nanoparticles (Karnik et al., 2008; Zhigaltsev et al.,
2012). This reaction takes place at the interface of the solvent and
aqueous streams. Liposome formation is based on polarity
alterations throughout the chamber and an increase in the surface
area of the ﬂuid interface occurs, as the ﬂuids are folded over on top
of each other aided by the channel design and grooves on the
channel ﬂoor (Fig. 1, small). The rate of polarity increase and the
subsequent following the formation of liposomes is user-con-
trolled by alterations in ﬂow rates of the separate streams as well
the ratios of aqueous to solvent stream as demonstrated for
liposomes (Bally et al., 2012; Zhigaltsev et al., 2012) and polymeric
nanoparticles (Bally et al., 2012). Furthermore, the option of
parallelization of the mixing cartridges allows for scalability as a
high throughput method (Belliveau et al., 2012).
The development and optimization of new processes and
methods can be a time consuming task, especially when applying
the traditional one-factor-at-a-time (OFAT) method, where only
one factor is optimized while all other factors remain constant.
Adopting this approach may also result in the optimum process
or formulation being overlooked as well as possible factor-Fig. 1. Schematic of liposome formulation process. Lipids dissolved in ethanol and an a
chamber (small picture), designed with grooves on the channel ﬂoor to aid chaotic adv
critical quality attributes.interactions (Montgomery et al., 1997). An alternative approach
is to adopt design of experiments (DoE), a statistical optimization
method, favorably used in pharmaceutical and biopharmaceutical
process development and optimization (Lawrence, 2008; Singh
et al., 2011; Vandervoort and Ludwig, 2002). DoE is a systematic
approach of creating structured experiments, measuring or
detecting the effect of changes to a pre-deﬁned response. Product
quality, as well as process understanding is maximized with a
minimal number of experiments performed. In DoE, the factors are
deﬁned as the variables in a process and selected responses deﬁne
the properties of the system that is investigated. Factors are the
tools used for manipulation of the system, which following
inﬂuence the responses. The aim is to connect the variation in the
factors to the resulting responses, and link the information using a
mathematical model. DoE does not only investigate statistical
signiﬁcant factors involved in a process (main effects), it also
identiﬁes interactions between factors and respective inﬂuence on
the desired output variable (Eriksson, 2008; Mandenius and
Brundin, 2008). A second statistical tool, multivariate data analysis
(MVDA), allows for the analysis of more than one statistical
variable at a time by reducing dimensionality in a data set by its
transformation (Wold et al., 2001a,b,b). MVDA is used for
identifying patterns and relationships between several variables
simultaneously (Eriksson, 2006). It predicts the effect of changing
one variable to other variables and is applied for data analysis, data
mining, classiﬁcation (e.g., cluster analysis or outlier detection),
regression analysis and predictive modeling, frequently used in
pharmaceutical and biopharmaceutical processes (Eriksson, 2006;
Pasqualoto et al., 2007; Rathore et al., 2011). Both tools, DoE and
MVDA, are statistical-based, process understanding and optimiza-
tion tools that build and describe knowledge around a speciﬁc
application, which ultimately supports the development of
conﬁdence and enhanced understanding, as well as robustness
of a process.
This present study ﬁrst investigated microﬂuidics as a new
method for manufacturing of cationic liposomes using the
NanoAssemblrTM. To achieve this 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammo-
nium-propane (DOTAP) were used to formulate liposomes. This
combination of the fusogenic lipid DOPE with the cationic lipid
DOTAP, is a frequently used composition due to its high in vitroqueous buffer are injected into separate chamber inlets. Mixing takes place in the
ection between both streams. Depicted are the critical process parameters and the
Fig. 2. Liposome characteristics. (A) Vesicle size (z-average), (B) zeta potential and
(C) polydispersity of DOPE:DOTAP formulations manufactured by microﬂuidic
mixing. Results are the mean of triplicate formulations  SD.
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et al., 2010; Liu and Huang, 2002) and was therefore chosen to
allow correlation of the systems produced via this new production
method with previous studies.
2. Materials and methods
2.1. Materials
1,2-dioleoyl-sn-glycero-3-phsphoethanolamine (DOPE) and
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were pur-
chased from Avanti Polar Lipids, Inc., (Alabaster, AL) (purity >99%).
Ethanol and chloroform (all HPLC grade) were purchased from
Fisher Scientiﬁc (Leicestershire, UK). LipofectinTM reagent was
obtained from Invitrogen Life Technologies and the luciferase assay
kit and CellTiter 961AQueous One Solution Cell Proliferation Assay
were both obtained from Promega (Madison, WI). Serum free and
antibiotic free medium (opti-MEM), Dulbecco’s modiﬁed Eagles
medium (DMEM), L-glutamine/penicillin–streptomycin and foetal
bovine serum (FBS) were purchased from Gibco-Invitrogen Ltd.
(Paisley, UK) (all cell culture grade). gWizTM Luciferase was
obtained from Genovac GmbH, Germany. COS-7 cells (GMP grade)
were purchased from European collection of cell cultures (ECACC),
a Health Protection Agency Culture Collection (Salisbury, UK).
2.2. Micromixer
The micromixer was obtained from Precision NanoSystems Inc.,
with molded channels of 200 mm in width and 79 mm in height
with herringbone features of 50  31 mm in poly(dimethylsilox-
ane). Connections of disposable 1 mL syringes to the two inlet
streams to the chip was done by ﬂuid connectors. Liposome
formulations using the micromixer were performed on a benchtop
NanoAssemblrTM instrument (NanoAssemblrTM, Precision Nano-
Systems Inc.). The two inlet streams comprised lipids dissolved in
ethanol and aqueous buffer (Tris, 10 mM, pH 7.4), syringe pumps
allowed for controlling the ﬂow rates and the ﬂow ratios between
the two inlet streams.
2.3. Liposome preparation
DOPE and DOTAP (8:8 mmol) were dissolved in ethanol. Here,
an equal molar lipid ratio was used, a standard ratio in cationic
liposome-DNA transfection studies as reported previously (Felgner
et al., 1994; Moghaddam et al., 2011). The ethanol-lipid solution
was injected into the ﬁrst inlet and an aqueous buffer (Tris 10 mM;
pH 7.4) into the second inlet of the microﬂuidic mixer (Fig. 1).
During initial studies, the TFR of aqueous buffer and lipid phase
were varied from 0.5 mL/min to 2 mL/min and the FRR of the
solvent and aqueous phases was varied from 1:1 to 1:5. Values of
TFR and FRR were extrapolated from previous reported nano-
precipitation methods using a SHM design with a channel
diameter of 200 mm (Zhigaltsev et al., 2012) as well as based on
preliminary screening prior to this work. The resulting aqueous
dispersions of liposome formulations, as formed by the mixing of
the two adjacent streams, were collected from the outlet stream
and subsequently dialysed over night against Tris buffer (10 mM;
pH 7.4) to remove any residual solvent.
2.4. Liposome characterisation
The dynamic light scattering (DLS) technique was used to report
the intensity mean diameter (z-average) and the polydispersity of
all liposome formulations (Malvern Zetasizer Nano-ZS (Malvern
Instruments, Worcs., UK)). The measurements of vesicle size and
polydispersity were carried out at 25 C in Tris buffer (1/10 dilution;1 mM, pH 7.4). Liposome zeta potential was measured in Tris buffer
(1 mM, pH 7.4) using the Malvern Zetasizer Nano-ZS (Malvern
Instruments, Worcs., UK). All measurements were undertaken in
triplicates.
2.5. HPLC
Lipid quantiﬁcation of the liposome formulations was carried
out using an Agilient 1200 series HPLC connected to an SEDEX
90 evaporative light scattering detector (ELSD). A Phenomenex1
Luna 5 m C18 (2) 100 A 150  4.6 mm column was used. An isocratic
ﬂow method was employed with 85% methanol and 15% 0.1% TFA
water at a ﬂow rate of 1 mL/min. The ELSD temperature was set at
52 C. The total run time was 20 minutes.
2.6. DNA lipoplex preparation for in vitro transfection
To perform in vitro studies, lipoplexes was prepared by diluting
17.5 ml of SUV solution (16 mmol) to 0.35 mL with Opti-MEM, and
Fig. 4. (A) Comparison of transfection efﬁciency of cationic nanoparticles.
Liposomes were complexed with gWiz plasmid DNA expressing ﬁreﬂy luciferase.
(B) Relative cell viability of nanoparticles formulated with distilled water. Results
denote mean  SD, n = 3.
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incubation, 0.35 mL of Opti-MEM containing 3.5 mg plasmid
DNA was added, mixed with liposome solution and incubated
again for a further 15 min at room temperature. The resultant
lipoplex mixture was then diluted to a ﬁnal volume of 3.5 mL with
Opti-MEM. The lipid/DNA charge ratio for in vitro study was +1.7/1.
2.7. In Vitro transfection of COS-7Cells
African green monkey kidney cells (COS-7 cells) were cultured
at 37 C under 5% CO2 in Delbecco’s modiﬁed Eagles medium
(DMEM). Medium was supplemented with 4 mM L-glutamine, 10%
(v/v) foetal bovine serum (FBS), penicillin (100 mg/mL) and
streptomycin (100 mg/mL). 24 h prior to transfection, the COS-
7 cells were plated at a cell concentration of 1 105 cells/mL in
1 mL of medium in a 12-well plate and were incubated overnight.
Cells were washed with 1 mL of Opti-MEM before lipoplexes were
added to the cells. 1 mL of the SUV–DNA solution (0.0078 mmole
total lipid content containing 1 mg plasmid DNA) was added to
each well. Each transfection was performed in triplicate. After 5 h
of incubation time at 37 C in 5% CO2, the medium was replaced
with growth medium (DMEM) containing 10% FBS and the cells
were incubated for further 48 h. The transfection efﬁciency of each
formulation was measured by determination of the percentage of
luciferase activity in each sample to the control. In this study this
value is reported as luciferase activity (%) and Lipofectin was the
control transfection reagent.
2.8. Cytotoxicity study
Lipoplex formulations used in the cytotoxicity study were same
as described above. COS-7 cells were transferred on a 96-well plate
and incubated for 24 h at 37 C in DMEM medium. 20 mL of MTS
reagent (CellTiter 961 AQueous One Solution Cell Proliferation
Assay) was added to each well. The MTS reagent is bioreduced by
the cells into a red formazan product, which indicates the presence
of metabolically active cells. After 4 h incubation at 37 C, in a 5%
humid CO2 atmosphere, the quantity of produced formazan was
measured on microplate reader (Thermo Scientiﬁc Molecular
Spectrum plate reader) at A490, with the absorbance reading being
directly proportional to the number of living cells in the medium.
In this study, cell viability was calculated and expressed as a
percentage to the positive control (i.e., cells and medium).
2.9. Statistical analysis
All experiments were performed in triplicates with calculation
of means and standard deviations. Statistical signiﬁcance wasFig. 3. Quantiﬁcation and recovery (%) of lipids (DOPE + DOTAP) by HPLC. Results
are the mean of triplicate formulations  SD.determined by a one-way analysis of variance (ANOVA) on all data,
and determined to 0.05 conﬁdence intervals (p < 0.05).
2.10. Design of experiments
The signiﬁcance of the factors TFR (0.5–2 mL/min) and FRR
(1:1–1:5) on liposome size, polydispersity and transfection
efﬁciency were investigated in a design of experiments (DoE)
study (MODDE version 10.0, Umetrics). We used multiple linear
regressions (MLR), which ﬁts one response at a time, based on the
assumption that the responses are independent. A quadratic
response surface model (RSM) was performed. The collected data
was used to estimate the coefﬁcients of the model and assess for
statistical signiﬁcance. The sum of squares of the residuals was
minimized in the model. The aim was to obtain small variation for
the coefﬁcients and minimize the prediction errors, which was
achieved with least square regression analysis. Prediction plots
(response surfaces) were used for model interpretation and
assessment of optimal regions in the model prediction. Models
were validated by analysis of variance (ANOVA), which identiﬁed
the goodness of ﬁt and prediction (R2 and Q2) and the signiﬁcance
of each factor in the model. Regression model signiﬁcance test
identiﬁed the validity of a model by dividing the mean squares of
the regression by the mean square of the residual, which allowed
for determination of the probability value p. With p < 0.05, theTable 1
Coefﬁcient list for the responses size, zp and PDI. Coefﬁcients were
determined as statistically signiﬁcant (p < 0.05).
Response Signiﬁcant coefﬁcients
Size (nm) TFR, FRR, FRR*FRR
PDI FRR, FRR*FRR
Transfection efﬁciency FRR, FRR*FRR
Table 2
ANOVA for the responses size, z and PDI. The p-statistics were analysed as well as
the Lack-of-ﬁt (LOF), together with ﬁt power (R2) and predictive power (Q2).
ANOVA Size PDI Transfection efﬁciency
Regression p 0.000 0.001 0.001
LOF p 0.255 0.973 0.585
R2 0.989 0.885 0.889
Q2 0.963 0.789 0.522
Model signiﬁcant? Yes Yes Yes
E. Kastner et al. / International Journal of Pharmaceutics 477 (2014) 361–368 365model determined was good. Lack of ﬁt (LOF) test was performed
to investigate the model error and the replicate error. A model
showed no lack of ﬁt when a sufﬁciently small model error and a
good data ﬁt were obtained, indicated by a p-value larger than the
critical reference 0.05.
2.11. Multivariate data analysis
Principal Component Analysis (PCA) and Partial Least Square
(PLS) regression analysis was performed (SIMCA version 13.0,
Umetrics) in order to analyse more than one variable at a time. The
relationship between the variables TFR and FRR and the responses
(liposome size, polydispersity and transfection efﬁcacy) was
displayed in a loading plot, using all experimentally obtained
raw data in this study. Weights were selected to maximize the
correlation. For interpretation, a line from a selected variable was
drawn though the origin and X- and Y-variables were projected on
the line. Variables opposite to each other were determined as
negatively correlated, positive correlation was determined with
variables adjacent to each other.
3. Results and discussion
3.1. Liposome manufacturing by microﬂuidics–vesicle size can be in-
process controlled.
Liposomes consisting of 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-Fig. 5. The response surface plots in the DoE study for the responses size (A), PDI (B)
and transfection efﬁcacy (C) as a function of ﬂow rate ratio and total ﬂow rate. All
three models were determined as statistical signiﬁcant in an ANOVA analysis.phosphoethanolamine (DOPE) were formulated using the micro-
ﬂuidics method with a SHM design. In this study, the aim was to
optimise parameters to control particle size by varying the TFR
from 0.5 mL/min to 2 mL/min and varying the FRR of the solvent/
aqueous phases from 1:1 to 1:5. It can be seen from Fig. 2A that as
the aqueous/ethanol FRR was increased, a reduction in liposome
size was detected. However, increasing the TFR from 0.5 mL/min to
2 mL/min did not signiﬁcantly affect the vesicle size for the FRR of
1:1, 1:3 and 1:5 (Fig 2A). Liposomes formed at 1:5 solvent/aqueous
formulation were smaller in size and around 50–75 nm compared
to the 1:1 solvent/aqueous formulation (175–200 nm; Fig. 2A). The
FRR strongly affects the polarity increase throughout the chamber
as well as the ﬁnal solvent concentration. At higher FRR (1:5), the
ﬁnal solvent concentration is reduced, thus reducing the produc-
tion of larger liposomes due to particle fusion and lipid exchange
(Ostwald ripening) after complete mixing is achieved. Previous
work using hydrodynamic ﬂow-focusing techniques have also
reported the decrease in liposome size with the increase in FRR
(Jahn et al., 2010; Zook and Vreeland, 2010), in agreement with
results in this study. The zeta potential of the liposomes formed
using this method was maintained despite alterations in ﬂow rates
and ratios with the liposomes had a positive zeta potential of
around 45–60 mV (Fig. 2B). This is in agreement with data
previously reported for DOPE:DOTAP prepared by the lipid-
hydration method following sonication (McNeil et al., 2010).
Furthermore, homogenous suspensions were quickly achieved
using the microﬂuidics method as the polydispersity was around
0.2–0.5 (Fig. 2C); the increase in FRR had the highest impact on
resulting PDI.
Overall, vesicle size was shown to be in-process controlled
through the aqueous/ethanol ﬂow rate ratio. The TFR was shown to
have no signiﬁcant effect on the liposome size, zeta potential and
polydispersity indicating the potential of the microﬂuidics system
to work at higher volumetric ﬂow rates and higher production
outputs, which represents a key advantage of the microﬂuidics-
based manufacturing of liposomes.
3.2. Lipid content quantiﬁcation by ELSD
To investigate the lipid recovery of formulations manufactured
at different TFR and FRR in the NanoAssemblrTM, we quantiﬁed the
lipids in the liposome formulations. Lipid composition is usually
quantiﬁed via high performance liquid chromatography after
extraction of the lipids in an organic phase. Here, we used an
evaporative light scattering detector (ELSD); a mass analyzer that
allows for quantiﬁcation of lipids based on light scattering. We
quantiﬁed the lipid content (DOPE and DOTAP) in each formulation
separately and related to it the initial lipid amount present in the
solvent stock. The liposome formulations were prepared in the
NanoAssemblrTM at ﬂow rates from 0.5 mL/min to 2 mL/min and
FRR of 1:1, 1:3 and 1:5 (solvent: aqueous ratio). Lipid recovery was
above 87% for all formulations, with no signiﬁcant differences
(p > 0.05) within all experiments (Fig. 3). This suggests that lipid
content remains independent of ﬂow rates and ﬂow ratios in the
NanoAssemblrTM and conﬁrms the suitability of the microﬂuidics
method for producing small liposomes with high lipid recovery.
Fig. 6. Results from the PLS regression analysis colored according to model term.
(A) Coefﬁcient plot including 95% conﬁdence interval for the two principal
components. (B) The loading scatter plot indicating signiﬁcance of the factors (X)
and responses (Y) to each other.
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efﬁciency
To consider the efﬁcacy of the liposome systems prepared using
microﬂuidics, their ability as transfection agents was tested using a
standard in vitro assay. The commercially available LipofectinTM
was used as a control since it has been extensively used to transfect
a wide variety of cells (Fortunati et al., 1996; Malone et al., 1989)
and a plasmid containing the luciferase gene (gWizTM Luciferase)
was used. The transfection efﬁciency of each formulation was
determined by measuring the percentage of luciferase activity in
each sample to the control (LipofectinTM) reported as luciferase
activity (%) (Fig. 4A). Whilst in general the liposomes prepared at a
solvent/aqueous ﬂow rate of 1:3 gave the highest transfection rate,
changes in the total ﬂow rate did not signiﬁcantly inﬂuence the
liposomes transfection activity again demonstrating this method
of liposome production is applicable for high-throughput produc-
tion of liposomes (Fig. 4A). The size, charge and lipid/NDA ration
have previously been shown to effect transfection efﬁciency
(Aljaberi et al., 2007; Caracciolo et al., 2007). Given that the lipids/
DNA ratio, as well as the cationic zeta potential has been constant
in each lipoplex formulation, the resulting difference in transfec-
tion efﬁcacy may be due to differences in liposome sizes (Fig. 2A) as
previously investigated (McNeil et al., 2010; Esposito et al., 2006;
Felgner et al., 1987; Kawaura et al., 1998).
The potential toxicity of these formulations was tested to verify
that transfection efﬁcacy was independent of cell viability and
toxicity. Overall, cell viabilities remained above 60% for all
experiments performed with no signiﬁcant (p > 0.05) difference
between the formulations (Fig. 4B). Neither the ﬂow rates nor the
ﬂow ratios were shown to affect the cell viability. Any gene delivery
vector should ideally be of low toxicity, and should additionally be
easy to manufacture in a robust and reproducible process (Lui and
Huang, 2003). Here, the microﬂuidics process was shown to fulﬁl
those requirements.3.4. Statistical signiﬁcance of the factors ﬂow rate ratio and total ﬂow
rate–design of experiment studies
Given that the liposomes prepared by microﬂuidics were shown
to be effective gene delivery vehicles and that the process
parameters adopted were shown to impact on their efﬁcacy, the
statistical signiﬁcant effect of the factors TFR and FRR on liposome
size, polydispersity and transfection efﬁciency (luciferase activity)
were further investigated in a response surface modeling in a DoE
study. Here, a quadratic interaction model investigated the factors
TFR and ﬂow rate ratio FRR as well as the interaction terms
TFR*TFR, FRR*FRR and TFR*FRR.
The signiﬁcant model terms determined in the model are
shown in Table 1. The signiﬁcant factors in the size model (FRR,
TFR, FRR*FRR) suggested that both factors together control the
liposome size manufactured with the NanoAssemblrTM. The
signiﬁcant interaction term of FRR*FRR suggests the importance
of the solvent/aqueous ratios to the overall liposome size,
emphasizing the FRR to be of high importance when controlling
the liposome size in a microﬂuidics method. The response surface
plots (Fig. 5) shows the combinatorial effect of alterations in FRR
and TFR in the NanoAssemblrTM process to the liposome size,
polydispersity and transfection efﬁcacy. The model predicted
minimal vesicle sizes of 60 nm for high ﬂow rates (2 mL/min) and
at high ﬂow rate ratios (1:5). This underlies the theory of liposome
formation by microﬂuidic mixing in the NanoAssemblrTM. The
increase in aqueous phase (ﬂow and volume) increases the amount
of polar phase available and thus enhances the rate of polarity
increase, shown by the signiﬁcant interaction term FRR*FRR
(Table 1). This affects the nanoprecipitation reaction, as smaller
vesicles should be generated with a higher amount of polar phase
available, emphasizing the theory of nanoprecipitation reaction
and liposome formation in the microﬂuidic mixing method. In the
ANOVA analysis (Table 2) we could identify the statistical
signiﬁcance of the models generated, where all three models
(size, polydispersity and transfection efﬁcacy) generated were
determined as statistical signiﬁcant.
The predictions for the PDI model identiﬁed the coefﬁcient FRR
as the only signiﬁcant model term (Table 2). The mathematical
model conﬁrmed statistical signiﬁcance for the factor FRR as the
only impact to the liposome PDI. Low PDIs were predicted for low
FRRs (1:1) (Fig. 5B), the increase in FRR, which lead to an increase
in PDI was already observed above (Fig. 2C) and conﬁrmed that the
PDI will inevitably increase once the FRR will be increase in the
process. The model for the transfection efﬁciency further
conﬁrmed the signiﬁcance of the factor FRR to resulting luciferase
activity. Luciferase activities above 180% were predicted for FRR
between 1:2 and 1:4, independent of the TFR used (Fig. 5C). These
predictions allow for targeted selection of ﬂow properties in the
micromixer depended on desired vesicle characteristics and
transfection efﬁciencies anticipated. These ﬁndings further under-
line the suggestions that the alterations of the TFR mainly lead to
an increase in productivity by enhancing the throughput in the
method.
3.5. Correlation of factors in the microﬂuidics process to biological
responses and particle characteristics – multivariate data analysis
Multivariate analysis tools are frequently used to ﬁnd relation-
ships amongst variables (X) and response (Y). Partial least square
(PLS) analysis deals with X and Y variables, and is used for
regression modeling of X and Y. It can be used to predict Y from X
and reveals how the variables and responses are related to each
other. Principal components (PC) are ﬁtted through the multidi-
mensional data set in order to generate coordinates of each data
E. Kastner et al. / International Journal of Pharmaceutics 477 (2014) 361–368 367point, which are used to plot the data set onto a plane in a loading
plot, which can be subsequently used for data interpretation.
In this study, two PCs were added in the PLS analysis, which
were depicted in the loading scatter plot in order to evaluate the
effect of factors (TFR and FRR) to the responses (liposome size, PDI
and transfection efﬁcacy). The coefﬁcient plot (Fig. 6A) reveals the
signiﬁcance of the factors as well as the responses for the two
principal components ﬁtted to the data set. Here, the factor TFR
was the only factor signiﬁcant in the second PC. The factor FRR, as
well as the responses transfection efﬁcacy and size were shown to
be highly statistical signiﬁcant in the ﬁrst principal component
(Fig. 6A). The response PDI was signiﬁcant in both principal
components. The loading scatter plot (Fig. 6B) indicated that the
TFR was in the upper left quadrant, opposite to the response
liposome size. The coefﬁcient plot (Fig. 6A) identiﬁed that the
factor TFR and the response size were signiﬁcant in different PCs,
which indicates no correlation. Furthermore, the response PDI was
the only further response signiﬁcant in the second PC, which
suggests that the factor TFR is independent of liposome size and
transfection efﬁciency. Furthermore, the FRR factor was shown to
directly correlate to the liposome polydispersity (Fig. 6B), both
highly signiﬁcant in the ﬁrst PC, which has been previously seen in
the DoE model (Table 1). Thus, the analysis predicts an increase in
polydispersity in a liposome formulation once the FRR is increased.
The correlation between the responses size and transfection
efﬁciency indicated, as both responses are situated closely adjacent
to each other in the loading plot, both signiﬁcant in the ﬁrst PC, a
direct correlation (Fig. 6B). This indicates that the increase in
liposome size results in a higher transfection efﬁciency, which has
been seen in the above DoE model and gives a mathematical proof
of previous ﬁndings; larger particles correlate with greater level of
transfection efﬁciency than smaller complexes at constant lipid/
DNA ratio (McNeil et al., 2010; Esposito et al., 2006; Felgner et al.,
1987; Kawaura et al., 1998).
The factor FRR was shown to have the highest impact to the
responses, indicated by a very small 95% conﬁdence interval in the
coefﬁcient plot (Fig. 6A). As seen in the DoE study, the FRR was
shown to be highly signiﬁcant in the size, PDI and transfection
efﬁciency model. Therefore, we can conclude that FRR needs
crucial optimization in a formulation in order to develop a method
with not only desired particle characteristics (size and PDI) but also
in the case of this formulation the anticipated transfection
efﬁciencies for in-vitro gene delivery and application of lipoplexes.
Overall, the results indicate that the FRR in the microﬂuidic process
has a strong relevance to the formation of size-controlled vesicles
with MVDA studies conﬁrm the signiﬁcance of FRR in the
microﬂuidics process for the formation of liposomes.
The systematic application of statistical based process control
and optimization requires not only fewer experiments to ﬁnd a
local optima, it also it reveals factor interactions and can be used
for process simulations. Overall, it will lead to better understand-
ing of a process, which assists in development and scale-up. It is a
cost-effective method providing deep understanding in a process
(Singh et al., 2005). Gabrielsson et al., 2002 reviewed multivariate
methods in pharmaceutical applications, which range from
factorial designs to multivariate data analysis and regression
analysis, where studies reported improved process and product
quality. Where DoE is frequently used to ﬁnd local optima, PCA and
PLS are mainly applied to gain deeper understanding and
information about a process and the effect of how factors inﬂuence
the responses. In this study, we have developed a statistical valid
regression model, which allows for prediction of liposome sizes,
polydispersity and transfection efﬁciencies as a function of
variables in the microﬂuidics-based manufacturing method.
Furthermore, the application of MVDA allowed for deeper
understanding of process settings that will lead to increasedprocess control with a deﬁned product quality outcome. The
combination of multivariate methods and experimental design in
any pharmaceutical or biopharmaceutical process development
strategies is a powerful tool towards developing new processes and
ﬁnding optima within a deﬁned region of factors by speeding up a
developing process.
4. Conclusion
In this paper, we have used a microﬂuidics-based liposome
manufacturing method and varied the process parameters total
ﬂow rate and ﬂow rate ratio to produce liposomes of deﬁned size.
Using microﬂuidics, homogenous liposomes suspensions can be
prepared in a high throughput method setup. Liposomes
manufactured by this method were shown to give reproducible
transfection results in standard transfection protocols. The
application of statistical-based methods (design of experiments
and multivariate data analysis) revealed the mathematical
relationship and signiﬁcance of the factors total ﬂow rate and
ﬂow rate ratio in the microﬂuidics process to the liposome size,
polydispersity and transfection efﬁcacy. We show that the here
applied methods and mathematical modeling tools can efﬁciently
be used to model and predict liposome size, polydispersity and
transfection efﬁcacy as a function of the variables in the micro-
ﬂuidics method. Furthermore, the advantages of microﬂuidics as a
bottom-up liposome manufacturing method have been shown,
anticipating microﬂuidics and associated lab-on-a-chip applica-
tions will become the choice of liposome manufacturing in future.
With these studies, we have demonstrated the advantages of
incorporating additionally statistical based methods into a
development process. Application of statistical based process
control and optimization tools like DoE and MVDA will enhance
the reproducibility in a process and aid for generation of a design
space. This will increase the understanding and conﬁdence in a
process setting and allow for predictive and correlative compar-
isons between the critical process parameters and their effect on
desired critical quality attributes, leading to a desired and robust
product quality
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